Uses and misuses of definitions of genetic polymorphism: A perspective from population pharmacogenetics

dc.creatorArias, Tomas D.
dc.creatorJorge, L. F.
dc.creatorBarrantes Mesén, Ramiro
dc.date.accessioned2016-01-15T17:19:43Z
dc.date.accessioned2019-04-25T14:37:16Z
dc.date.available2016-01-15T17:19:43Z
dc.date.available2019-04-25T14:37:16Z
dc.date.created2016-01-15T17:19:43Z
dc.date.issued1991
dc.identifierhttp://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.1991.tb03870.x/abstract
dc.identifier1365-2125
dc.identifierhttp://hdl.handle.net/10669/15491
dc.identifier10.1111/j.1365-2125.1991.tb03870.x
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/2372413
dc.description.abstractDefinitions of genetic polymorphism currently employed in the pharmacological literature have been incorrectly used (Kalow, 1984) and uncritically imported from population genetics [e.g., Weinshilboum (1984), Evans (1977)], apparently without regard to the problems their application might present in pharmacogenetics or, more specifically, in pharmacogenetic studies of populations.
dc.languageen_US
dc.sourceBritish Journal of Clinical Pharmacology 31:117-119
dc.subjectfarmacogenesis
dc.subjectpolimorfismo
dc.subjectGenética humana
dc.subjectGenética
dc.titleUses and misuses of definitions of genetic polymorphism: A perspective from population pharmacogenetics
dc.typeArtículos de revistas
dc.typeArtículo científico


Este ítem pertenece a la siguiente institución